A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial

被引:9
|
作者
Shin, Dongho [1 ]
Ha, Seunggyun [2 ]
Hyun, O. Joo [2 ]
Rhew, Seung Ah [1 ]
Yoon, Chang Eil [1 ]
Kwon, Hyeok Jae [1 ]
Moon, Hyong Woo [1 ]
Park, Yong Hyun [1 ]
Park, Sonya Youngju [2 ]
Park, Chansoo [3 ]
Chi, Dae Yoon [3 ]
Yoo, Ie Ryung [2 ]
Lee, Ji Youl [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Urol, Seoul 06591, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Nucl Med, Seoul 06591, South Korea
[3] FutureChem Co Ltd, Res Inst Labeling, Seoul 04793, South Korea
基金
新加坡国家研究基金会;
关键词
metastatic castration-resistant prostate cancer; lutetium-177; PSMA; radiopharmaceutical therapy; RADIONUCLIDE THERAPY;
D O I
10.3390/cancers14246225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Prostate specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed in prostate cancer cells. For patients with metastatic castration-resistant prostate cancer (mCRPC) who do not respond to conventional treatment, PSMA targeting radiopharmaceutical therapy (RPT) has recently been in the spotlight. [Lu-177]Ludotadipep is a novel PSMA-targeting therapeutic agent designed with an albumin motif in order to increase the circulation time and uptake in the tumors. The safety and efficacy of [Lu-177]Ludotadipep were evaluated through a phase I trial. [Lu-177]Ludotadipep, which enables targeted delivery of beta-particle radiation to prostate tumor cells, had been suggested as a promising therapeutic option for mCRPC. From November 2020 to March 2022, a total of 30 patients were enrolled for single dose of [Lu-177]Ludotadipep RPT, 6 subjects in each of the 5 different activity groups of 1.9 GBq, 2.8 GBq, 3.7 GBq, 4.6 GBq, and 5.6 GBq. [Lu-177]Ludotadipep was administered via venous injection, and patients were hospitalized for three days to monitor for any adverse effects. Serum PSA levels were followed up at weeks 1, 2, 3, 4, 6, 8, and 12, and PSMA PET/CT with [F-18]Florastamin was obtained at baseline and again at weeks 4 and 8. The subjects required positive PSMA PET/CT prior to [Lu-177]Ludotadipep administration. Among the 29 subjects who received [Lu-177]Ludotadipep, 36 treatment emergent adverse events (TEAEs) occurred in 17 subjects (58.6%) and 4 adverse drug reactions (ADRs) in 3 subjects (10.3%). Of the total 24 subjects who had full 12-week follow-up data, 16 (66.7%) showed decrease in PSA of any magnitude, and 9 (37.5%) showed a decrease in PSA by 50% or greater. A total of 5 of the 24 patients (20.8%) showed disease progression (PSA increase of 25% or higher from the baseline) at the 12th week following single dose of [Lu-177]Ludotadipep. These data thus far suggest that [Lu-177]Ludotadipep could be a promising RPT agent with low toxicity in mCRPC patients who have not been responsive to conventional treatments.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ha, Seunggyun
    Hyun, O. Joo
    Park, Chansoo
    Boo, Sun Ha
    Yoo, Ie Ryung
    Moon, Hyong Woo
    Chi, Dae Yoon
    Lee, Ji Youl
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (02) : 179 - 188
  • [2] Results of phase 2 study of [177Lu]Ludotadipep for metastatic castration-resistant prostate cancer
    Kwon, S.
    Lee, J.
    Park, C.
    Min, J.
    Ha, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S328 - S328
  • [3] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [4] Clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
    Unterrainer, Lena
    De Leiris, Nicolas
    Unterrainer, Marcus
    Ilhan, Harun
    Delker, Astrid
    Hempel, Linus
    Ells, Zachary
    Zahner, Joseph
    Holzgreve, Adrien
    Zacherl, Mathias J.
    Casuscelli, Jozefina
    Kiraz, Kevin
    Leenhardt, Julien
    Jacquet, Emmanuelle
    Long, Jerome
    Laramas, Mathieu
    Paller, Channing Judith
    Solnes, Lilja B.
    Gafita, Andrei
    Djaileb, Loic
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 39 - 39
  • [5] Dosimetry and pilot therapy study of novel PSMA-targeting agents, [177Lu]Lu-P17-087 and [177Lu]Lu-P17-088, in metastatic castration-resistant prostate cancer patients
    Li, Linlin
    Wang, Jiarou
    Wang, Guochang
    Wang, Rongxi
    Jin, WenBin
    Zang, Jie
    Sui, Huimin
    Jia, Chenhao
    Jiang, Yuanyuan
    Hong, Haiyan
    Zhu, Lin
    Alexoff, David
    Ploessl, Karl
    Kung, Hank
    Zhu, Zhaohui
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [6] LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Kostos, Louise
    Buteau, James P.
    Kong, Grace
    Opar, Petra
    Di Lulio, Juliana
    Fahey, Michael
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 77 - 77
  • [7] LuCAB: A PHASE I/II TRIAL EVALUATING CABAZITAXEL IN COMBINATION WITH (177Lu)Lu-PSMA-617 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Buteau, James
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 71 - 71
  • [8] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [9] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [10] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276